• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research

Atrial fibrillation, cancer and anticancer drugs
Arch Cardiovasc Dis. 2023 Mar 11:S1875-2136(23)00058-X. doi: 10.1016/j.acvd.2023.02.005. Online ahead of print.ABSTRACTActive cancer is associated with an increased risk of atrial fibrillation (AF), which varies depending on the pre-existing substrate (particularly in older patients), the cancer type and stage, and the anticancer therapeutics being taken. To date, studies have not been able to identify the individual contribution of each factor. During anticancer drug therapy, AF may occur with a frequency of ≈ 15-20% according to several factors, including the patient's baseline cardiovascular toxicity risk and the AF-d...
Source: Cancer Control - March 31, 2023 Category: Cancer & Oncology Authors: Jonaz Font Paul Milliez Alexandre-Boudjema Ouazar Frederikus A Klok Joachim Alexandre Source Type: research

Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis
CONCLUSION: Current clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.PMID:36136141 | DOI:10.1007/s00228-022-03383-2
Source: Clinical Lung Cancer - September 22, 2022 Category: Cancer & Oncology Authors: Xiaomei Wang Demei Zhang Yanxia Ren Jingjing Han Guangling Li Xueya Guo Source Type: research

Cancers, Vol. 13, Pages 4012: Atrial Fibrillation after Lung Cancer Surgery: Prediction, Prevention, and Anticoagulation Management
rdinale Atrial fibrillation (AF) is a common complication of the early postoperative period of various types of surgery, including that for lung cancer. Although induced by the homeostatic alterations related to surgery, there is evidence that it is not a mere stand-alone transitory event, but it represents a relevant complication of surgery, bearing considerable prognostic consequences. Different methods have therefore been explored to predict the occurrence of postoperative atrial fibrillation (POAF) and prevent it. In particular, the age among clinical factors, and N-terminal prohormone of brain natriuretic peptide ...
Source: Cancers - August 9, 2021 Category: Cancer & Oncology Authors: Gennaro Semeraro Carlo Meroni Carlo Cipolla Daniela Cardinale Tags: Review Source Type: research

Cancers, Vol. 13, Pages 4012: Atrial Fibrillation after Lung Cancer Surgery: Prediction, Prevention and Anticoagulation Management
rdinale Atrial fibrillation (AF) is a common complication of the early postoperative period of various types of surgery, including that for lung cancer. Although induced by the homeostatic alterations related to surgery, there is evidence that it is not a mere stand-alone transitory event, but it represents a relevant complication of surgery, bearing considerable prognostic consequences. Different methods have therefore been explored to predict the occurrence of postoperative atrial fibrillation (POAF) and prevent it. In particular, the age among clinical factors, and N-terminal prohormone of brain natriuretic peptide ...
Source: Cancers - August 9, 2021 Category: Cancer & Oncology Authors: Gennaro Carmine Semeraro Carlo Ambrogio Meroni Carlo Maria Cipolla Daniela Maria Cardinale Tags: Review Source Type: research

Beta-blockers in Pediatric Hypertrophic Cardiomyopathies.
Conclusions: Beta-blocker therapy is without doubt the treatment of choice for patients with heart failure caused by hypertrophic cardiomyopathy, but the dose needs to carefully titrated on an individual basis for maximum benefit, and the dose required is surprisingly large in infants with heart failure due to hypertrophic cardiomyopathy. PMID: 25198737 [PubMed - as supplied by publisher]
Source: Reviews on Recent Clinical Trials - September 8, 2014 Category: Cancer & Oncology Authors: Ostman-Smith I Tags: Rev Recent Clin Trials Source Type: research